ophthalmology

News

eyeDNA plans pivotal trial of retinitis pigmentosa therapy

Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regul

News

Boehringer raises hope of diabetic macular ischaemia therapy

Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet

News

Palatin pummelled as dry eye therapy underwhelms in phase 3

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

News

4DMT gene therapy cuts need for Eylea in wet AMD trial

A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease age-related macular degeneration (AMD) 4D-150 has shown promising signs of efficacy, plus a red

News

Sandoz makes its first post-spinout acquisition

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in

News

Roche builds gene therapy portfolio with SpliceBio deal

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

eyeDNA plans pivotal trial of retinitis pigmentosa therapy

Boehringer raises hope of diabetic macular ischaemia therapy

Palatin pummelled as dry eye therapy underwhelms in phase 3

4DMT gene therapy cuts need for Eylea in wet AMD trial

Sandoz makes its first post-spinout acquisition

Roche builds gene therapy portfolio with SpliceBio deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

ophthalmology

Editor's Picks